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Patient-reported outcomes (PROs), including symptoms and health-related quality of life (HRQOL), provide
a patient-centered description of hematopoietic cell transplantation (HCT)-related toxicity. These data
characterize the patient experience after HCT and may have prognostic usefulness for long-term outcomes
after HCT. We conducted a study of 32 patients after HCT (10 autologous HCT recipients, 11 full-intensity
conditioning allogeneic HCT recipients, and 11 reduced-intensity conditioning allogeneic HCT recipients) to
determine the feasibility of weekly electronic PRO collection from HCT until day (D) þ100. We used questions
from the PRO version of the Common Terminology Criteria for Adverse Events to capture symptoms, and the
Patient-Reported Outcomes Measurement Information System Global Health scale to measure physical and
mental HRQOL. The vast majority (94%) of patients used the electronic PRO system, with only 6% opting for
paper-and-pencil only. The median weekly percentage of participants who completed the surveys was 100%
in all cohorts through hospital discharge, and remained 100% for the autologous HCT and reduced-intensity
allogeneic HCT cohorts through Dþ100. Patients were satisﬁed with the electronic system, giving high marks
for readability, comfort, and questionnaire length. Symptom severity varied by absolute level and type of
symptom across the 3 cohorts, with the full-intensity allogeneic HCT cohort exhibiting the greatest median
overall symptom severity, peaking at Dþ7. Median physical health HRQOL scores decreased with time in the 3
cohorts, and HRQOL was generally correlated with overall symptom severity. Our results demonstrate the
feasibility of frequent electronic PROs in the early post-HCT period. Future studies in larger populations to
explore predictive models using frequent PRO data for outcomes, including long-term HRQOL and survival,
are warranted.
 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.INTRODUCTION
Hematopoietic cell transplantation (HCT) is a life-saving
or life-extending treatment for incurable or advanced
hematologic malignancies [1]. The efﬁcacy and widespread
application of this therapy is limited by transplantation-
related toxicity and functional impacts. A clearer under-
standing of who is at risk for transplantation-related toxicity
and how to limit this effect is needed to effectively counsel
patients before HCT, to make transplantation available for
others who might beneﬁt from it, and to ameliorate long-
term quality-of-life deﬁcits associated with treatment-
related toxicity.
Traditionally, transplantation-related toxicity has been
measured by the metrics transplantation-related mortality
(TRM) or nonrelapse mortality (NRM). Short of death, prev-
alent and signiﬁcant morbidities include graft-versus-hostedgments on page 457.
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12.11.014disease (GVHD), infection, and conditioning-related organ
dysfunction. Patient-reported outcomes (PROs), including
symptoms and health-related quality of life (HRQOL),
measure and describe transplantation-related toxicity from
the patient’s perspective [2,3]. Changes in symptoms
describe the patient experience over time and may help
predict the future. HRQOL can also describe beneﬁcial
patient-centered effects of transplantation, including
freedom fromunderlying disease-related disability and long-
term spiritual growth [4].
A growing body of literature documents the impact of
HCT on HRQOL. Several studies have reviewed the trajectory
of HRQOL over time after HCT, demonstrating early impair-
ment in HRQOL, followed by eventual recovery in most, but
not all, long-term survivors [5,6]. Periodic and infrequent
HRQOL assessments by traditional measures, such as the
Functional Assessment of Cancer TherapyeBone Marrow
Transplant (FACT-BMT), M.D. Anderson Symptom Inventory
(MDASI), and SF-36, have been used.
Although frequent assessment of symptoms and HRQOL
in the early posttransplantation period using PROs has not
been explored extensively, this approach offers several
potential advantages for the study of transplantation-relatedTransplantation. Published by Elsevier Inc. All rights reserved.
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clinician-reported outcomes when evaluating the effects in
HCT [10,11]. These include (1) characterizing and differenti-
ating the patient-reported impact of discrete conditioning
regimens [12,13]; (2) exploring the relationship between
symptoms and early HRQOL as a possible mediator of long-
term HRQOL impairment; (3) identifying early patient-
reported predictors of long-term mortality, morbidity, and
decreased HRQOL; and (4) informing the use of strategies,
such as exercise and supportive care interventions, that
might relieve symptoms and improve HRQOL.
Techniques involving frequent survey administration
must be convenient, acceptable, and feasible for patients
experiencing the acute effects of conditioning chemotherapy,
all of whom will be hospitalized for at least some portion of
this time. In addition, contemporary methods of assessing
symptomatic toxicity and HRQOL in cancer patients, such as
the PRO version of the Common Terminology Criteria for
Adverse Events (PRO-CTCAE) and the Patient-Reported
Outcomes Measurement Information System (PROMIS),
might be applicable, but have yet to be well tested in patients
undergoing HCT.
The purpose of the present study was to investigate the
feasibility and acceptability of frequent electronic-based
symptom and HRQOL assessment, using questions derived
from PRO-CTCAE and PROMIS, in the early post-HCT period.
METHODS
Patients
Patients were approached for enrollment into the feasibility study if
they were over 18 years of age, could read English, and were able to provide
informed consent. Patients were identiﬁed in the outpatient, pre-
transplantation environment through discussions with transplantation
nurse coordinators, advanced practice providers, or attending physicians.
The 3 planned cohorts, with a targeted enrollment of 10 patients per cohort,
included patients undergoing planned autologous HCT, patients undergoing
full-intensity conditioning allogeneic HCT, and patients undergoing
reduced-intensity conditioning allogeneic HCT.
Once patients were identiﬁed and deemed eligible to participate in the
study, those interested in enrolling were asked to sign an informed consent
form approved by the University of North Carolina’s Lineberger Compre-
hensive Cancer Center Protocol Review Committee and the University of
North Carolina’s Biomedical Institutional Review Board.
Survey Selection
The National Cancer Institute’s (NCI) PRO-CTCAE measurement system
allows patients to self-report symptomatic adverse events (AEs) [14]. The
items are intended to be complementary to items in the NCI’s Common
Terminology Criteria for Adverse Events (CTCAE), an existing lexicon of
clinician-reported adverse event items required for use in all NCI-sponsored
trials [15]. The PRO-CTCAE item library comprises 124 items that assess
different attributes (eg, presence, frequency, worst severity, interference
with usual or daily activities) of 80 symptoms represented in the CTCAE
version 4 AE lexicon. PRO-CTCAE items use a 7-day recall period, and
response options for all attributes are on a 0-4 Likert scale, except for
“present/not present” items, which are binary.
Only PRO-CTCAE severity items were selected for administration in this
study. PRO-CTCAE severity items ask patients to rate the worst severity of
a speciﬁc symptom during the speciﬁed period of recall with 1 of 5 response
choices (none, mild, moderate, severe, or very severe). For the purposes of
this study, 34 symptom severity questions (see the Appendix) considered
relevant to patients undergoing HCT were selected from the PRO-CTCAE
item library by the study team and administered weekly to patients, using
a 7-day recall period, according to the schedule described below. An overall
weekly symptom burden score was calculated by summing the score for
each symptom question (range, 0-4) to obtain a ﬁnal score ranging from 0-
136. Higher scores represent a greater symptom burden. In contrast to the
34 weekly symptom questions, 21 severity items from the PRO-CTCAE were
administered daily, using a 24-hour recall period, according to the schedule
described below. The daily survey data are not reported here.
The PROMIS Global Health scale is a 10-question HRQOL assessment tool
that elicits information on patients’ perceived quality of life, general func-
tioning and overall health, pain, and symptoms of depression or anxiety[16]. A physical health score and mental health score were derived from the
PROMIS Global Health scale, each using 4 separate questions. The scores
were calibrated on a T-score metric normed with a general population
sample with a mean of 50 and a standard deviation of 10 [16]. Higher scores
reﬂect better HRQOL. For the purpose of this study, the PROMIS Global
Health scale was administered weekly to patients, according to the schedule
described below (see the Appendix).
A separate 9-question satisfaction survey was also administered to
evaluate patients’ satisfaction and general ease of use of the electronic
symptom-reporting system, according to the schedule described below (see
the Appendix) [17].
Survey Administration
Patients were invited to take all surveys electronically, although paper-
and-pencil versions of each survey were available for all patients at each
time point for those who opted to use this method, based on data indicating
the equivalence of these 2 modes of survey administration [18]. Electronic
surveyswere administered using a HIPAA-compliant survey tool provided by
Qualtrics (Provo, UT). Surveys were administered on study-provided elec-
tronic tablets or on patients’ personal computers or mobile phones,
dependingonpatient preference. Surveyswere accessible fromaprivateWeb
site, and were accessed securely by a unique URL e-mailed daily to each
patient. A research coordinator introduced each patient to the electronic
survey system andwas available for follow-up questions; speciﬁc training on
theelectronicplatformbeyondthiswasnotprovidedor foundtobenecessary.
Survey Schedules
Patients in all cohorts were asked to complete the weekly PRO-CTCAE
and PROMIS Global Health surveys at the time of study enrollment (base-
line), on the ﬁrst day of conditioning chemotherapy, and weekly from day
0 (D0, receipt of stem cell infusion) to day 100 after stem cell infusion
(Dþ100). Autologous HCT recipients were asked to complete daily PRO-
CTCAE surveys from the ﬁrst day of conditioning chemotherapy until
initial hospital discharge. Allogeneic HCT recipients (both full-intensity and
reduced-intensity conditioning) were asked to complete daily PRO-CTCAE
surveys from the ﬁrst day of conditioning chemotherapy until Dþ100. All
patients were asked to complete satisfaction surveys after completing the
ﬁrst PRO surveys, on the ﬁrst day of conditioning chemotherapy, on D0, and
on Dþ100.
Statistical Methods
Feasibility was deﬁned as >60% of approached patients enrolling in the
study, and >70% weekly symptom survey completion among those enrolled
[17]. Secondary objectives of the study included determining the time spent
completing the surveys and assessing patient satisfaction with the survey
system. Descriptive statistics, correlations, and graphical analyses were used
to explore symptom proﬁles through Dþ100, examine differences in indi-
vidual and aggregate symptoms and HRQOL among cohorts and patients,
and investigate correlations between individual symptoms and HRQOL.
Most continuous measures are presented as median and interquartile
range (25th-75th percentiles) and are compared between cohorts using the
Kruskal-Wallis test. Owing to the 5-level rating system for individual
symptom scores, means were used to rank the symptoms from highest to
lowest severity at each time point. To evaluate changes over time within
cohorts for the symptom severity and Global physical health and mental
health scores, the range of scores for each patient was calculated, and these
ranges were then compared among cohorts, also using Kruskal-Wallis tests.
Spearman correlation coefﬁcients were used to measure correlations
between symptoms and HRQOL. All analyses were performed using SAS
version 9.2 (SAS Institute, Cary, NC).
RESULTS
Patients
Of the 47 patients approached for enrollment into the
study, 32 (68%) agreed to participate. The electronic PRO
survey assessments were part of a larger study that also
required extensive baseline and follow-up exercise testing,
and reasons that potential enrollees provided for declining
included unwillingness to participate in baseline exercise
testing and/or unwillingness to return for follow-up exercise
testing. Among potential patients who declined, only 1
patient speciﬁcally identiﬁed the survey requirements as
a reason for declining participation. Thus, a minimum of 68%
of approached patients were willing to participate in this
frequent survey-based study.
Table 1
Baseline Descriptive Data
Autologous
(n ¼ 10)
Allogeneic
(Full-
Intensity)
(n ¼ 11)
Allogeneic
(Reduced-
Intensity)
(n ¼ 11)
Total
(n ¼ 32)
Age at HCT, years,
median
59.8 49.7 61.2 57.8
Sex, n (%)
Male 5 (50) 3 (27) 8 (73) 16 (50)
Female 5 (50) 8 (73) 3 (27) 16 (50)
Race, n (%)
African American 2 (20) 2 (18) 0 (0) 4 (13)
Asian 0 (0) 1 (9) 0 (0) 1 (3)
Caucasian 8 (80) 7 (64) 11 (100) 26 (81)
Hispanic 0 (0) 1 (9) 0 (0) 1 (3)
Education, n (%)
Less than high
school
1 (10) 1 (9) 0 (0) 2 (6)
Completed high
school
4 (40) 6 (55) 1 (9) 11 (34)
College degree or
higher
5 (50) 4 (36) 10 (91) 19 (59)
Diagnosis, n (%)
AML 0 (0) 7 (63) 6 (55) 13 (41)
ALL 0 (0) 2 (18) 1 (9) 3 (9)
Multiple myeloma 8 (80) 0 (0) 0 (0) 8 (25)
CML 0 (0) 1 (9) 0 (0) 1 (3)
MDS 0 (0) 1 (9) 1 (9) 2 (6)
NHL 2 (20) 0 (0) 2 (18) 4 (13)
Aplastic anemia 0 (0) 0 (0) 1 (9) 1 (3)
Cancer stage [19],
n (%)*
Early 2 (20) 1 (9) 2 (20) 5 (16)
Intermediate 8 (80) 5 (46) 4 (40) 17 (55)
Late 0 (0) 5 (46) 4 (40) 9 (29)
HCT-CI score [20],
n (%)
0 4 (40) 2 (18) 3 (27) 9 (28)
1 1 (10) 0 (0) 1 (9) 2 (6)
2 1 (10) 1 (9) 3 (27) 5 (16)
3 1 (10) 3 (27) 1 (9) 5 (16)
4 3 (30) 1 (9) 1 (9) 5 (16)
5 0 (0) 2 (18) 2 (18) 4 (13)
7 0 (0) 2 (18) 0 (0) 2 (6)
EBMT score [19],
n (%)
0-1 0 (0) 0 (0) 0 (0) 0 (0)
2 2 (20) 2 (18) 0 (0) 4 (13)
3 4 (40) 2 (18) 2 (18) 8 (25)
4 4 (40) 4 (36) 6 (55) 14 (44)
5 0 (0) 3 (27) 1 (9) 4 (13)
6 0 (0) 0 (0) 2 (18) 2 (6)
7 0 (0) 0 (0) 0 (0) 0 (0)
* Aplastic anemia was not staged.
W.A. Wood et al. / Biol Blood Marrow Transplant 19 (2013) 450e459452Demographic data for our patients are presented in
Table 1. A total of 32 patients were enrolled into 3 cohorts: 10
autologous HCT recipients, with either melphalan or BEAM
conditioning; 11 full-intensity allogeneic HCT recipients,
typically with full-dose busulfan and ﬂudarabine condi-
tioning; and 11 reduced-intensity allogeneic HCT recipients,
typically with reduced-dose busulfan and ﬂudarabine
conditioning. The median age at the time of transplantation
for the entire cohort was 57.8 years. Thirteen patients (41%)
had a high school education or less. Seventeen patients (55%)
had intermediate disease, and 9 patients (29%) had advanced
disease [19]. Sixteen patients (50%) had a Hematopoietic Cell
Transplantation-Speciﬁc Comorbidity Index [20] score of 3.Feasibility
All patients were offered the opportunity to use the
electronic mode of survey assessment on study-providedtablets or individual personal computers or mobile phones.
Two patients (6%) opted to use paper-and-pencil only, and all
others used the electronic system. Weekly electronic
completion of 34 PRO-CTCAE items required a median of 4.3
minutes, and 10 PROMIS items were completed in a median
of 3 minutes. Three patients (9%; 1 full-intensity allogeneic
HCT recipient and 2 reduced-intensity allogeneic HCT
recipients) died before Dþ100. The median weekly
percentage of participants who took the surveys was 100% in
all cohorts from the start of conditioning up to hospital
discharge. The median completion rate remained 100%
through Dþ100 in the autologous HCT and reduced-intensity
allogeneic HCT cohorts, but was lower in the full-intensity
allogeneic HCT cohort (80%; P ¼ .002).
Satisfaction
Based on satisfaction questionnaire data, the patients
indicated that the survey questions were not difﬁcult to read
(responses of at least 94% at each time point), that the
questionnaire length was not too long (responses of at least
82% at each time point), and that using a computer to ﬁll out
the surveys was comfortable (responses of at least 88% at
each time point). At Dþ100, 73% of patients indicated that
the surveys helped them discuss medical issues with their
healthcare provider, and 80% responded that the surveys
helped remind them of symptoms that they had been
experiencing. Overall, the patients were satisﬁed with the
electronic survey questionnaires (responses of at least 94% at
each time point) and would recommend the electronic
survey questionnaires to others (responses of 81% at base-
line, 82% at D0, and 92% at Dþ100). Complete satisfaction
questionnaire data are presented in Table 2.
Symptoms
Table 3 lists the 5 most severe symptoms for each cohort
at baseline, D0 (day of stem cell infusion, after completion of
conditioning chemotherapy), Dþ7 (1 week after stem cell
infusion, close to the expectedWBC nadir and expected peak
symptom severity), Dþ28 (approximately 1 month after
stem cell infusion), and Dþ100 (end of the symptom
reporting period). Insomnia and fatigue were common in
most cohorts and time points, with other symptoms and
their severity varying by cohort and time point. Mean
“worst” severity scores across cohorts and time points for the
10 symptoms with the highest overall severity scores across
the entire period of analysis are presented in Figure 1,
ordered by severity.
Table 4 and Figure 2 present median symptom severity
scores for the 34 symptoms and the PROMIS physical and
mental health scores for each cohort and time point. Patients
in the full-intensity allogeneic HCT cohort reported the
highest overall median symptom scores, peaking at 38.0 at
Dþ7 (from 12.0 at baseline) and decreasing to 19.0 by the end
of the analysis period. In contrast, patients in the reduced-
intensity allogeneic HCT cohort reported a median overall
symptom score of 17.0 at Dþ7 (from 9.0 at baseline),
decreasing to 6.5 by Dþ100. Patients in the autologous HCT
cohort reported scores between those of the 2 allogeneic HCT
cohorts. Statistically signiﬁcant differences in summed
symptom severity scores among the 3 cohorts were seen at
Dþ0 (P ¼ .004) and Dþ7 (P ¼ .006), and a borderline statis-
tically signiﬁcant difference was seen at Dþ28 (P ¼ .07).
Overall symptom scores varied signiﬁcantly over time in the
full-intensity allogeneic HCT cohort, with a median range in
scores of 26, compared with 18 in the autologous HCT cohort
Table 2
Satisfaction Questionnaire
Question Response Baseline, % (n/N)* D0, % (n/N)* Dþ100, % (n/N)*
1. Readability of questions Not difﬁcult 94 (16/17) 100 (17/17) 100 (13/13)
2. Questionnaire length Not long 100 (20/20) 82 (14/17) 93 (14/15)
3. Ease using computer Comfortable 88 (15/17) 100 (17/17) 92 (12/13)
4. Helps in discussing medical issues with doctor Yes 21 (4/19) 35 (6/17) 73 (11/15)
No/don’t know 42 (8/19) 47 (8/17) 27 (4/15)
Haven’t yet seen doctor 37 (7/19) 18 (3/17) 0 (0/15)
5. Reminds you of symptoms Yes 53 (10/19) 65 (11/17) 80 (12/15)
No/don’t know 37 (7/19) 29 (5/17) 20 (3/15)
Haven’t yet seen doctor 11 (2/19) 6 (1/17) 0 (0/15)
6. Satisﬁed with computer questionnaire Satisﬁed 94 (16/17) 100 (17/17) 100 (13/13)
7. Recommend computer questionnaire to others Yes 81 (13/16) 82 (14/17) 92 (12/13)
No/don’t know 19 (3/16) 18 (3/17) 8 (1/13)
* n, number of patients who endorsed response option; N, total number of patients who responded to a question.
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(P ¼ .009).HRQOL
Table 4 and Figure 3 provide graphical depictions of
median PROMIS Global physical health and mental health T-
scores. Median physical health scores were not signiﬁcantly
different among cohorts at baseline (47.7 for the full-
intensity allogeneic HCT cohort, 49.3 for the autologous
HCT cohort, and 54.1 for the reduced-intensity allogeneic
HCT cohort; P¼ .50). Physical health scores decreased at Dþ7
to 39.1 in the full-intensity allogeneic HCT cohort, 48.4 in the
reduced-intensity allogeneic HCT cohort, and 42.7 in the
autologous HCT cohort. Differences in median physical
health scores among the 3 cohorts were statistically signiﬁ-
cant at Dþ0 (P ¼ .005) and Dþ7 (P ¼ .035). Variations in
physical health scores did not differ signiﬁcantly over time,
with a median range in scores of 14.8 in the autologous HCT
cohort, 10.3 in the full-intensity allogeneic HCT cohort, and
10.3 in the reduced-intensity allogeneic HCT cohort (P ¼ .30).
Median mental health scores ranged from 50.8 to 52.1 at
baseline, decreasing to a low at Dþ28 of 48.3 in the full-
intensity allogeneic HCT cohort, 52.1 in the reduced-
intensity allogeneic HCT cohort, and 47.1 in the autologous
HCT cohort. Differences in median mental health scores
among the 3 cohorts reached statistical signiﬁcance at Dþ0
(P ¼ .008). Mental health scores varied over time, with
a median range of 8.6 in the autologous HCTcohort, 7.7 in the
full-intensity allogeneic HCT cohort, and 5.7 in the reduced-
intensity allogeneic HCT cohort (P ¼ .50).Table 3
Top Symptoms (Ordered by Highest Mean “Worst” Severity Ratings) by Cohort ove
Baseline D0
Autologous 1. Insomnia 1. Insomnia
2. Pain 2. Hair loss
3. Joint aches 3. Urinary freque
4. Fatigue 4. Dry skin
5. Constipation 5. Pain
Allogeneic (full-intensity) 1. Insomnia 1. Fatigue
2. Fatigue 2. Pain
3. Pain 3. Nausea
4. Anxiety 4. Appetite
5. Joint aches 5. Tasting food
Allogeneic (reduced-intensity) 1. Insomnia 1. Insomnia
2. Fatigue 2. Appetite
3. Dry mouth 3. Urinary freque
4. Hair loss 4. Fatigue
5. Numbness/tingling 5. Tasting foodCorrelations
Moderate to strong negative correlations were observed
between overall symptom scores and physical health scores
at most time points, with strong negative correlations also
observed between overall symptom scores and mental
health scores at several of the same time points. Correlation
coefﬁcients are reported in Table 5.DISCUSSION
Our results conﬁrm the feasibility and acceptability of
frequent symptom and HRQOL sampling in the early post-
HCT period, and suggest several advantages and potential
future applications of this approach. Among enrolled
patients, many had advanced malignancies and signiﬁcant
comorbid illness, several were over age 60 years, and
a signiﬁcant minority (40%) had a high school education
or less. All patients were undergoing HCT, an intensive
inpatient procedure characterized by signiﬁcant overall
transplantation-related toxicity and periods of severe illness.
Nonetheless, completion rates of weekly 44-item symptom
and HRQOL surveys were very high in the overall sample.
Rates were signiﬁcantly lower between hospital discharge
and Dþ100 in the full-intensity allogeneic HCT cohort
compared with the other 2 cohorts, although still high
overall (80%). This difference might reﬂect intercurrent
illness in this cohort after hospital discharge, and future
studies should investigate the relationship (and potential
predictive value) of incomplete surveys with morbidity.
Across all cohorts, patient-reported satisfaction with ther Time
Dþ7 Dþ28 Dþ100
1. Tasting food 1. Fatigue 1. Pain
2. Appetite 2. Appetite 2. Insomnia
ncy 3. Fatigue 3. Dry skin 3. Fatigue
4. Diarrhea 4. Hair loss 4. Dry skin
5. Nausea 5. Nausea 5. Joint aches
1. Tasting food 1. Hair loss 1. Fatigue
2. Mouth sores 2. Tasting food 2. Anxiety
3. Appetite 3. Fatigue 3. Limb swelling
4. Fatigue 4. Appetite 4. Tasting food
5. Pain 5. Insomnia 5. Dry skin
1. Appetite 1. Fatigue 1. Fatigue
2. Insomnia 2. Insomnia 2. Insomnia
ncy 3. Fatigue 3. Appetite 3. Dry skin
4. Urinary frequency 4. Tasting food 4. Dry mouth
5. Tasting food 5. Dry skin 5. Itchy skin
Figure 1. Mean symptom severity. Patients reported symptoms weekly using a 34-question subset of the PRO-CTCAE. Depicted are mean severity scores for
10 individual symptoms over time by cohort (autologous, full-intensity allogeneic, and reduced-intensity allogeneic).
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Table 4
Weekly Symptom, Physical, and Mental Health Scores by Treatment over Time
Cohort Baseline D0 Dþ7 Dþ28 Dþ100
Weekly Symptom score,
median (IQR)*
Autologous 18.5 (8.0-33.0) 14.5 (8.0-22.0) 23.0 (18.0-36.0) 22.0 (16.0-27.0) 13.0 (4.0-18.0)
Allogeneic (full-intensity) 12.0 (6.0-20.0) 26.0 (26.0-37.0) 38.0 (29.0-43.0) 27.0 (21.5-39.5) 19.0 (7.0-27.0)
Allogeneic (reduced-intensity) 9.0 (4.0-22.0) 16.0 (6.0-25.0) 17.0 (12.0-29.0) 14.5 (9.0-23.0) 6.5 (4.5-20.5)
Physical Health score,
median (IQR)y
Autologous 49.3 (42.3-57.7) 50.8 (44.9-57.7) 37.4 (37.4-44.9) 41.1 (36.2-52.5) 52.7 (45.0-61.9)
Allogeneic (full-intensity) 47.7 (42.3-54.1) 38.6 (37.4-39.8) 37.4 (32.4-44.9) 39.8 (37.4-47.7) 47.7 (42.3-54.1)
Allogeneic (reduced-intensity) 54.1 (47.7-57.7) 47.7 (47.7-57.7) 47.7 (44.9-54.1) 47.7 (42.3-54.1) 50.8 (42.3-54.1)
Mental Health score,
median (IQR)y
Autologous 52.1 (50.8-59.0) 53.3 (50.8-59.0) 50.8 (45.8-59.0) 47.1 (41.2-57.5) 54.7 (47.2-61.8)
Allogeneic (full-intensity) 50.8 (48.3-56.0) 45.8 (43.5-48.3) 53.3 (41.1-53.0) 48.3 (38.8-53.3) 48.3 (36.3-53.3)
Allogeneic (reduced-intensity) 53.3 (48.3-59.0) 53.3 (50.8-59.0) 53.3 (53.3-59.0) 52.1 (48.3-56.0) 56.0 (50.8-59.0)
* Higher score is indicative of worse symptom burden.
y Higher score is indicative of better health.
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high.
The electronic method of survey administration has
several potential advantages over paper-and-pencil surveys
[17,18,21]. Electronic surveys are adaptable, particularly in
the context of our study design, in which computerized links
were sent daily to study participants. In the future, this
approach could accommodate skip logic and computerized-
adaptive testing technology [22] to reduce respondent
burden. Electronic PRO collection also enhances the efﬁ-
ciency of survey administration and data aggregation,
possibly allowing this approach to be scaled to larger
multisite studies with heterogeneous populations. Finally,
encouraging patient comfort and familiarity with an elec-
tronic interface during the posttransplantation period allows
for the opportunity to build software for additional future
purposes, such as education and reminders for medications
and other critical elements of self-care during this period.
Our results demonstrate the feasibility of applying
symptom and HRQOL PROmeasures, such as PRO-CTCAE and
PROMIS, that have not been studied previously in the HCT
population. PRO-CTCAE and automated symptom reporting
in general have proven useful in the non-HCT cancer pop-
ulation [14,23-25]. The PRO-CTCAE’s ability to capture key
HCT-related symptoms in our study population suggests the
need for further validation of this measure in HCT recipients
and applications similar to those developed and tested in
non-HCT patients. PROMIS has been extensively validated in
cancer and noncancer populations and provides useful
reference points for comparison with the general US pop-
ulation [26]. Additional validationwithin the HCT population
could lead to useful potential comparisons of HRQOL in this
population and populations with other cancers and chronicFigure 2. Median overall symptom scores. Weekly scores for individual
symptoms were summed to provide an overall weekly symptom score. Shown
are median weekly symptom scores for each of the 3 cohorts. Higher scores
represent worse symptom burden.illnesses undergoing treatment. Other patient-reported
outcome measures of symptoms and HRQOL have been
used successfully in HCT recipients [5,10,11,27]. Formal
comparisons of the PROMIS and PRO-CTCAE with those
measures was beyond the scope of the present study,
however. Although many of the same symptoms and HRQOL
domains are included in all of these measures, they differ in
some ways, including reference period, item phrasing,
length, and scoring metric. We believe that investigators
should select the measure most appropriate for their
particular study design.
Although our analyses were exploratory in nature, our
results demonstrate the potential usefulness of frequent
patient reporting of symptoms and HRQOL during this time
period. We were able to demonstrate that symptom scores
changed over time, increasing and decreasing in ways
consistent with expected physiological changes as the resultFigure 3. Median HRQOL (physical health and mental health) scores. Weekly
scores for the 10-question PROMIS Global Health measure were used to
determine weekly physical health and mental health scores. Shown are
median weekly physical health and mental health scores for each of the 3
cohorts. Lower scores represent worse physical health and mental health.
Table 5
Correlation of Weekly Symptom Scores with Weekly Physical and Mental
Health Scores (Spearman Correlations)
Autologous Allogeneic
(Full-Intensity
Conditioning)
Allogeneic
(Reduced-
Intensity
Conditioning)
Baseline
Symptoms versus
Physical Health
score
0.57 0.69 0.66
Symptoms versus
Mental Health
score
0.54 0.59 0.85
Day þ0
Symptoms versus
Physical Health
score
0.48 0.86 0.83
Symptoms versus
Mental Health
score
0.34 0.15 0.70
Day þ7
Symptoms versus
Physical Health
score
0.50 0.70 0.80
Symptoms versus
Mental Health
score
0.20 0.45 0.74
Day þ28
Symptoms versus
Physical Health
score
0.52 0.45 0.45
Symptoms versus
Mental Health
score
0.57 0.07 0.52
Day þ100
Symptoms versus
Physical Health
score
0.79 0.87 0.75
Symptoms versus
Mental Health
score
0.80 0.72 0.63
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effects. These changes also differed by cohort in predictable
ways, consistent with the literature [7] (eg, full-intensity
allogeneic HCT recipients experienced the greatest
symptom burden, around the time of predicted WBC count
nadir), supporting the validity of these measurements.
Individual symptoms also changed over time and by cohort
in unique ways, demonstrating the differential composition
of the overall symptom burden for different cohorts. Our
sample size did not permit a detailed analysis of which
patient subsets within each cohort were most symptomatic
and why; this topic could be explored in future studies using
predictive modeling to examine the relationship between
symptoms and long-term outcomes.
Likewise, HRQOL varied predictably over time and by
cohort. Our data suggest that in particular, changes in phys-
ical HRQOL appeared tomirror changes in symptoms. Mental
health HRQOL changes appeared to be less consistent in our
dataset, however. Reasons for this might be related to our
small sample size, characteristics of the PROMIS mental
health questions that are less well suited to an HCT recipient
population, or perhaps early mental health HRQOL changes
as a phenomenon distinct from physical health HRQOL.
Further studies are needed to investigate this issue more
speciﬁcally.
Our data conﬁrm the ﬁndings of Cohen et al. [7], in which
symptoms as measured by MDASI-BMT peaked, individually
and in aggregate, at the nadir of WBC count withcorresponding decrements in HRQOL. Differences in PROs by
conditioning regimen were also seen in both studies.
Although our ﬁndings conﬁrm these data, additional
advantages offered by our approach include the demon-
strated feasibility of more frequent assessment (ie, weekly
and even daily, although these data are not reported here), as
well as an expanded inventory of symptom assessment
questions provided by the PRO-CTCAE.
In general, our data demonstrate that symptom sampling
can be used to measure the longitudinal impact of speciﬁc
treatments on physiological functioning over time. Our
observed correlations between symptoms and HRQOL, and
the corresponding changes in symptoms with physical and
mental HRQOL, reﬂect a potential mechanism for decreased
HRQOL among HCT recipients. A larger dataset might allow
the differentiation of discrete trajectories between physical
and mental HRQOL, as well as the identiﬁcation of which
symptoms (and which speciﬁc treatment effects) are most
closely related to the observed variation in each. These data
also might help guide such strategies as exercise interven-
tions, stress management, and other supportive care
approaches to ameliorate symptom and HRQOL decline and
potentially improve long-term outcomes.
We acknowledge several potential limitations to this
study. Because this was a feasibility study, our sample size
was necessarily small. All of the patients in the study were
hospitalized for the duration of conditioning chemotherapy
and posttransplantation engraftment, facilitating an
extended learning period for the electronic survey system. At
other centers, some patients are outside of the hospital for
much of the peritransplantation period. However, our
patients continued to use the electronic survey system after
discharge in the outpatient environment. In addition, we
were not able to formally compare different HRQOL scales
(eg, SF-36, FACT-BMT) with PROMIS, or different symptom
burden scales (MDASI) [26,27] with PRO-CTCAE, leaving the
optimal method for obtaining these data in HCT recipients
unclear. We did not attempt to obtain frequent PRO data for
survivors beyond Dþ100, and did not study long-term
symptom burden [28,29]. Finally, we did not use these data
as part of routine clinical care; future work might formally
investigate the clinical utility of these scales and evaluate
whether frequent symptom or HRQOL reporting could
inform day-to-day clinical decisions.
In addition to these limitations, we also were able to
identify important challenges that will need to be considered
as these types of studies are expanded in the future. A clear
advantage of electronic PRO capture relates to the minimal to
modest costs of ongoing survey administration and data
aggregation. Software development costs are up front and
likely feasible for research-based data collection, although
they would be increased if PRO data were to be made avail-
able at the point of care to inform decision making. Finally,
although our surveys were associated with high patient
satisfaction and response rates, it is likely that research
coordinators with experience in the PRO software system
will be needed in larger studies to maintain response rates
and limit missing data. This suggestion is consistent with
recently published recommendations for integrating PROs
into comparative effectiveness research [30].
We envision several directions for further development of
this work. Studies are planned to investigate whether daily
symptom data are additionally informative to weekly
symptom data. Models will be constructed to evaluate
whether symptom clusters can be identiﬁed within the data
W.A. Wood et al. / Biol Blood Marrow Transplant 19 (2013) 450e457 457collected, providing further information about the speciﬁc
physiological effects of the HCT process on patients. In the
future, multisite efforts should be developed to expand this
approach to a larger HCT recipient population. These efforts
might incorporate biomarker data and could be designed to
determine whether early symptom and HRQOL data can be
incorporated into predictive models for intermediate and
long-term transplantation-related toxicity, such as GVHD,
long-term HRQOL impairment, and TRM. Similar models
relying on electronic PRO capture could be developed for
other transplantation-related disease states as well, such as
acute or chronic GVHD, with PROs tailored to the expected
symptoms and impact of these disease states on patient
functioning and experience. With these models, early inter-
ventions could then be targeted to high-risk patients to limit
transplantation-related morbidity and TRM, and help
improve the therapeutic index of transplantation for patients
with life-threatening diseases.ACKNOWLEDGMENTS
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Symptoms Assessed Daily
1. Bloating of the abdomen (belly)
2. Constipation
3. Loose or watery stools (diarrhea)
4. Mouth or throat sores
5. Nausea
6. Shivering or shaking chills
7. Fatigue, tiredness, or lack of energy
8. Pain
9. Decreased appetite
10. Problems with concentration
11. Dizziness
12. Headache
13. Problems with memory
14. Anxiety
15. Sad or unhappy feelings
16. Insomnia (including difﬁculty falling asleep, staying
asleep, or waking up early)
17. Cough
18. Shortness of breath
19. Dry skin
20. Itchy skin
21. Rash
Symptoms Assessed Weekly
1. Bloating of the abdomen (belly)
2. Constipation
3. Loose or watery stools (diarrhea)
4. Dry mouth
5. Mouth or throat sores
6. Nausea
7. Difﬁculty swallowing
8. Vomiting
9. Blurry vision
10. Arm or leg swelling
11. Easy bruising (black and blue marks)
12. Shivering or shaking chills
13. Fatigue, tiredness, or lack of energy
14. Pain
15. Decreased appetite
16. Joint aches (such as elbows, knees, shoulders)
17. Muscle aches
18. Problems with concentration
19. Dizziness
20. Headache
21. Problems with memory
22. Numbness or tingling in hands or feet
23. Problems with tasting food or drink
24. Anxiety
25. Sad or unhappy feelings
26. Insomnia (including difﬁculty falling asleep, staying
asleep, or waking up early)
27. Frequent urination
28. Loss of control of urine (leakage)
29. Cough
30. Shortness of breath
31. Dry skin* The Global physical health score is generated by summing responses to
Global03, Global06, Global07 (rescored), and Global08 (rescored). The
Global mental health score is generated by summing responses to Global02,
Global04, Global05, and Global10 (rescored).32. Hair loss
33. Itchy skin
34. Rash
HRQOL Questionnaire*
(Global01) In general, would you say your health is:
Excellent/Very Good/Good/Fair/Poor
(Global02) In general, would you say your quality of life
is:
Excellent/Very Good/Good/Fair/Poor
(Global03) In general, how would you rate your physical
health?
Excellent/Very Good/Good/Fair/Poor
(Global04) In general, how would you rate your mental
health, including your mood and your ability to think?
Excellent/Very Good/Good/Fair/Poor
(Global05) In general, how would you rate your satisfac-
tion with your social activities and relationships?
Excellent/Very Good/Good/Fair/Poor
(Global09) In general, please rate how well you carry out
your usual social activities and roles. (This includes
activities at home, at work and in your community, and
responsibilities as a parent, child, spouse, employee,
friend, etc).
Excellent/Very Good/Good/Fair/Poor
(Global06) To what extent are you able to carry out your
everyday physical activities such as walking, climbing
stairs, carrying groceries, or moving a chair?
Completely/Mostly/Moderately/A little/Not at all
(Global10) In the past 7 days: How often have you been
bothered by emotional problems such as feeling anxious,
depressed, or irritable?
Never/Rarely/Sometimes/Often/Always
(Global08) In the past 7 days: How would you rate your
fatigue on average?
None/Mild/Moderate/Severe/Very severe
(Global07) In the past 7 days: How would you rate your
pain on average?
0 ¼ No pain
1
2
3
4
5
6
7
8
9
10 ¼Worst imaginable pain
Satisfaction Survey
How easy was it to read the questions on your health?
Very difﬁcult/Difﬁcult/Neither difﬁcult nor easy/Easy/
Very easy
How easy was it to use the computer to respond to the
questions?
Very difﬁcult/Difﬁcult/Neither difﬁcult nor easy/Easy/
Very easy
How was the length of the questionnaire that you
completed today?
Very long/Long/Okay/Short/Very short
How comfortable was the computer to use?
Very uncomfortable/Uncomfortable/Neither comfort-
able nor uncomfortable/Comfortable/Very comfortable
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medical issues with your doctor that youmight otherwise
not have discussed?
No/Yes/I don’t know/I haven’t seen my doctor yet
Did the questionnaire help remind you of symptoms you
experienced such as stomach problems, headaches, or
anxious feelings?
No/Yes/I don’t know/I haven’t seen my doctor yetIn general, how satisﬁed were you with using the
computerized questionnaire to report your symptoms?
Very dissatisﬁed/Dissatisﬁed/Neither satisﬁed nor
dissatisﬁed/Satisﬁed/Very satisﬁed.
Would you recommend that other patients use the
computerized symptom questionnaire?
No/Yes/I don’t know
What can we do to make the questionnaire or computer
system better?
